Cytokinetics Insider Exercises Options Worth Over $920,000 as Heart Drug Hits the Market

15,000 shares were sold for approximately $928,950 at a weighted average price of $61.93 on Feb. 5, 2026. The sale represented 22.9% of Andrew Callos' direct holdings, reducing his position from 65,440 to 50,440 shares. This is a sizable insider sale by ownership percentage but is routine disclosure-level information with limited broader market impact.

Analysis

15,000 shares were sold for approximately $928,950 at a weighted average price of $61.93 on Feb. 5, 2026. The sale represented 22.9% of Andrew Callos' direct holdings, reducing his position from 65,440 to 50,440 shares. This is a sizable insider sale by ownership percentage but is routine disclosure-level information with limited broader market impact.